Background-Ischemic preconditioning provides strong cardioprotection from ischemia, but its molecular mechanisms remain unknown. Convincing evidence confirms a central role of hypoxia-inducible factor (HIF)-1 in mammalian oxygen homeostasis. Thus, we pursued HIF-1 as a central component of cardioprotection by ischemic preconditioning. Methods and Results-Murine studies of in situ preconditioning revealed a robust activation of cardiac HIF-1␣. Moreover, in vivo small interfering RNA repression of cardiac HIF-1␣ resulted in abolished cardioprotection by ischemic preconditioning.
I schemic preconditioning (IP) is defined as an experimental technique in which tissues are rendered resistant to the deleterious effects of ischemia/reperfusion injury by prior exposure to brief, repeated periods of vascular occlusion. For example, myocardial IP is associated with increased myocardial resistance to hypoxia, resulting in a profound reduction in myocardial infarct sizes. 1 Multiple studies have attempted to identify molecular mechanisms involved in cardioprotection by IP. For example, polygenic responses involving mediators such as adenosine, bradykinin, opioids, erythropoietin, adrenergics, muscarinic signaling pathways, or protein kinase C (PKC ) activation have been proposed. 2, 3 However, a profound reduction in morbidity and mortality from acute myocardial infarction, as would be expected from the initial observation, 1 has not been achieved in patients.
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Cardioprotection by IP involves alteration of the myocardial cellular phenotype to become more resistant to subsequent hypoxic tissue challenges. Over the past decade, convincing evidence has been shown that the transcription factor hypoxia-inducible factor (HIF)-1 has an essential role in the maintenance of oxygen homeostasis in mammalian organisms. 4 -13 A number of very elegant studies, exemplified by those defining induction of the erythropoietin (EPO) gene, 14, 15 have used multidisciplinary approaches to elucidate this pathway. HIF-1 exists as an ␣/␤ heterodimer, the activation of which depends on stabilization of an oxygendependent degradation domain of the ␣ subunit by the ubiquitin-proteasome pathway. 6, 16 HIF-1 appears to reside in the cytoplasm of normoxic cells, and like a number of other transcription factors, HIF-1 translocates to the nucleus to form a functional complex. 13 Subsequently, it was determined that HIF-1 is widely expressed and that consensus HIF-1 binding sequences exist in a number of genes other than EPO and are called hypoxia-responsive enhancers. 17 Thus, the discovery of HIF-1 represented a major advance in the understanding of gene regulation by hypoxia. 5,18 -20 Recent studies have more clearly defined the mechanisms that regulate HIF-1 activity. HIF expression depends predominantly on the degradation of the ␣ subunit in normoxia, which occurs through the ubiquitin-proteasomal pathway. 21, 22 Oxygen-dependent degradation of HIF-1␣ is triggered by binding of the von Hippel-Lindau tumor-suppressor protein (VHL), which interacts with the protein elongin C, resulting in proteasomal degradation. VHL binding depends on the hydroxylation of proline residue 402, 564, or both by the prolylhydroxylase 2 (PHD2). PHD1 and PHD3 also hydroxylate HIF-1␣ when overexpressed, but their physiological functions have not been established. PHD2 activity is reduced under hypoxic conditions as a result of either substrate limitation or inhibition of the catalytic center, resulting in stabilization of HIF-1␣. 4, 5 On the basis of the central role of HIF-1 in mammalian adaptation to hypoxia, we hypothesized a critical role of HIF-1␣ in coordinating cardioadaptive responses elicited by IP to render the heart more resistant to subsequent hypoxic episodes. To pursue this hypothesis, we used a recently developed model of murine in situ IP using a hanging-weight system for intermittent coronary occlusion that essentially avoids any surgical tissue trauma and results in highly reproducible infarct sizes. 23
Methods

Murine Model of Myocardial Ischemia and IP
Murine myocardial ischemia and IP were performed as described previously (for details, see the online-only Data Supplement). [23] [24] [25] Because previous studies in this model have revealed optimal cardioprotection with 4 cycles of IP treatment (5 minutes of ischemia, 5 minutes of reperfusion), 23 we used this regimen throughout the present study.
In Vivo Small Interfering RNA Repression
For in vivo small interfering RNA (siRNA) repression, a model of intraventricular siRNA infusion was developed (for details, see the online-only Data Supplement; siRNA sequences are summarized in supplemental Table I ). [23] [24] [25] 
Transcriptional Analysis, Western Blot Analysis, and Immunohistochemistry
Transcriptional analysis, Western blot analysis, and immunohistochemistry were performed as described previously (for details, see the online-only Data Supplement; primer sequences are summarized in supplemental Table II ). [23] [24] [25] 
Adenosine Measurements
Tissue adenosine levels were determined via high-performance liquid chromatography as described previously. [23] [24] [25] 
Pharmacological Agents
As described previously, the PKC inhibitor GF 109203X (Tocris Bioscience, Ellisville, Mo) was given intraperitoneally at a dose of 4.2 g 30 minutes before IP treatment. 24 
Data Analysis
Data were compared by 2-factor ANOVA with Bonferroni posttest or by Student t test when appropriate. Values are expressed as meanϮSD from 6 animals per condition. For analysis of changes in transcript, a 1-way ANOVA was carried out, and multiple comparisons between control and treatment groups were made with the Dunnett posttest. Data are expressed as meanϮSEM. Values of PϽ0.05 were considered statistically significant. For all statistical analyses, GraphPad Prism 5.0 software for Windows XP (GraphPad Software, San Diego, Calif) was used.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
In Situ IP Treatment Leads to Stabilization of Cardiac HIF-1␣ In Vivo
Transcriptional adaptation to hypoxia is currently an area of intense investigation, and convincing evidence has shown HIF to be a key transcriptional regulator of mammalian oxygen homeostasis and adaptation to limited oxygen availability. 4 -11 Because cardiac IP results in profound increases in myocardial resistance to ischemic tissue injury, we hypothesized a critical role of HIF-1 in transcriptional coordination of cardiac IP. To study this hypothesis, we used a previously described model of murine in situ IP via a hanging-weight system for intermittent coronary occlusion. [23] [24] [25] We first gained insight from studies of To study HIF-1 during myocardial IP, we performed in situ preconditioning consisting of 4 cycles of ischemia/reperfusion (5 minutes each) followed by indicated times of reperfusion. B, HIF-1␣ protein of myocardial biopsies from the area at risk. C57BL/6 mice were subjected to IP, and cardiac tissue from the area at risk was excised at the indicated time points, flash-frozen, and lysed; proteins were resolved by SDS-PAGE; and tissue was transferred to nitrocellulose. Membranes were probed with an anti-HIF-1␣ antibody. The same blot was probed for ␤-actin expression as a control for protein loading. One representative experiment of 3 is shown. C, Pretreatment with the PKC inhibitor GF 109203X. D, C57BL/6 mice were subjected to IP, and cardiac tissue from the area at risk was harvested 120 minutes after IP, sectioned, and stained with HIF-1␣ antibody. Unpreconditioned cardiac tissue from sham-operated mice served as control (magnification ϫ400). Note that although unpreconditioned myocardium showed only weak immunoreactivity, staining for HIF-1a was significantly increased after preconditioning. To control for nonspecific staining, IgG was used at identical concentrations and staining conditions as the target primary antibodies for HIF-1␣. A indicates anesthesia induction; T, thoracotomy. murine in situ IP followed by excision of preconditioned myocardial tissues at different time points after IP treatment ( Figure 1A ). We used these tissues to study HIF-1 activation by performing Western blot analysis for HIF-1␣. In fact, we found a robust and persistent stabilization of HIF-1␣ protein after IP treatment ( Figure 1B) . Consistent with previous studies showing PKC in cardioprotection by IP 2 and HIF stabilization, 26 IPassociated HIF stabilization was attenuated after treatment with a PKC inhibitor ( Figure 1C ). Immunohistochemical staining for HIF-1␣ in preconditioned myocardium localized HIF-1␣ to the cytosole and the nucleus of preconditioned myocardium ( Figure 1D ).
siRNA Repression of HIF-1␣ Abolishes Cardioprotection of IP Treatment
To study a functional contribution of HIF-1 to cardioprotection by IP, we next developed an in vivo siRNA technique to repress cardiac HIF-1␣. For this purpose, we infused a commercially available mixture of siRNA molecules specifically designed to target HIF-1␣ combined with a transfection reagent into the left ventricle. We advanced a carotid artery catheter into the left ventricle and confirmed its correct position by pressure monitoring ( Figure 2A ). Once the appearance of a diastolic left ventricular pressure reading confirmed the position of the catheter within the left ventricle (diastolic pressure, 5 to 10 mm Hg), the infusion of siRNA together with transfection agent (siPORT Amine, Ambion, Austin, Tex) was started (1.5 g of siRNA/g body weight; Figure 2A ). We then determined HIF-1␣ transcript levels at the indicated time points (0 to 2 hours) after the start of the siRNA infusion. These studies revealed maximal repression of HIF-1␣ transcript at 2 hours of infusion (0.20Ϯ0.14-fold reduction; PϽ0.05), with no additional changes in HIF-1␣ transcript levels with 4 hours of infusion (data not shown). In To pursue studies of cardiac in vivo siRNA repression, a surgically inserted carotid catheter (arrow) was advanced into the left ventricle (star). Blood pressure recording from the catheter confirmed correct placement of the catheter tip within the left ventricle. After correct placement of the catheter, an infusion of target or csiR, together with transfection agent (siPORT Amine), was given over the indicated time periods (1.5 g siRNA/g body weight). B, Changes in cardiac HIF-1␣ transcript after in vivo siRNA repression. C57BL/6 mice were treated with a left ventricular infusion (see above) of siRNA specific for HIF-1␣ or csiR. After the indicated time periods, hearts were excised, total RNA was isolated, and HIF-1␣ transcript levels were determined by real-time reverse-transcription polymerase chain reaction. Data were calculated relative to an internal housekeeping gene (␤-actin) and are expressed as fold change vs control (0 hour of siRNA infusionϮSEM at each indicated time; nϭ6). C, HIF-1␣ Western blot analysis of myocardial biopsies from the area at risk after HIF-1␣ repression. C57BL/6 mice were treated with control or HIF-1␣-specific siRNA over 2 hours before IP, and cardiac tissue from the area at risk was excised at the indicated time points, flash-frozen, and lysed; proteins were resolved by SDS-PAGE; and the tissue was transferred to nitrocellulose. Membranes were probed with an anti-HIF-1␣ antibody. The same blots were probed for ␤-actin expression as a control for protein loading. One representative experiment of 3 is shown. D, Increased infarct size and abolished cardioprotection by IP after siRNA repression of HIF-1␣. C57BL6 mice were anesthetized and, after left ventricular catheter placement, received a 2-hour infusion with control or HIF-1␣-specific siRNA/transfection agent (see above). Mice were subjected to 60 minutes of ischemia alone (Control [C]) or IP (4ϫ5 minutes) at the indicated time periods (0 to 240 minutes) before 60 minutes of ischemia. Mice were killed after 120 minutes of reperfusion, and infarct sizes were measured. Infarct sizes are expressed as percentage of the area at risk (meanϮSD; nϭ6). E, Troponin I plasma levels were measured by ELISA (meanϮSD; nϭ6).
contrast, transcript levels of HIF-1␣ were unchanged with infusion of the control siRNA (csiR). To determine whether other HIF isoforms are affected by this treatment, we also measured HIF-2␣ transcript levels. In fact, HIF-2␣ transcript levels were unchanged in HIF-1␣-siRNA-or control-siRNAtreated mice (data not shown). Similarly, increases in HIF-1␣ activity as measured from preconditioned myocardium by Western blot analysis confirmed HIF-1␣ activation with preconditioning in csiR-treated mice, whereas HIF-1␣ activation was abolished in mice treated with siRNA specific for HIF-1␣ ( Figure 2C ). Measurements of hemodynamic parameters (blood pressure and heart rate; supplemental Tables III and IV) revealed no off-target effects of siRNA treatment. To study functional consequences of HIF-1␣ repression, we exposed mice to 2 hours of HIF-1␣-siRNA or control-siRNA infusion, performed IP, and induced 60 minutes of myocardial ischemia at different time points after IP treatment (0 to 240 minutes). Although in control-siRNA-treated mice cardioprotection by IP was maximal at 4 hours after IP treatment, cardioprotection by IP was completely abolished in HIF-1␣-siRNA-treated mice ( Figure  2D and 2E). Taken together, these studies reveal that inhibition of the HIF-1␣ pathways is associated with abolished cardioprotective effects of IP treatment.
HIF Activator Dimethyloxaloylglycine Attenuates Myocardial Infarction
To study HIF activation in myocardial ischemia, we first pursued a pharmacological approach using the panhydroxylase inhibitor dimethyloxaloylglycine (DMOG), which is known to stabilize HIF-1␣ protein via nonspecific inhibition of PHD1, PHD2, and PHD3. 27 As a first step, we used different dosing regimens (0.01 to 1 mg/mouse) and timing intervals (1 to 12 hours) (data not shown), which revealed maximal HIF-1␣ activation Ͼ2 hours after 1 mg DMOG was given intraperitoneally ( Figure 3A and 3B ). Next, we used this pharmacological approach in functional studies. These studies revealed significant cardioprotection with DMOG (0.34Ϯ0.06-fold reduction in infarct size; Figure  3C ). This also was obvious from representative infarct staining ( Figure 3D ) or plasma troponin I levels ( Figure 3E ) but was abolished after HIF-1␣-siRNA repression. Taken together, these results suggest HIF activation by DMOG in attenuation of myocardial ischemia/reperfusion injury.
PHD2 Is Critical for HIF-1-Dependent Cardioprotection
We next pursued studies to gain more specific insights into the mechanisms of HIF-1 stabilization during cardiac IP. In fact, To study the effects of DMOG on cardiac HIF-1␣ activation, C57BL/6 mice were treated intraperitoneally with the indicated doses of DMOG (0.01 to 1 mg). Hearts were excised after 2 hours, flashfrozen, and lysed; proteins were resolved by SDS-PAGE; and the hearts were transferred to nitrocellulose. Membranes were probed with an anti-HIF-1␣ antibody. The same blot was probed for ␤-actin expression as a control for protein loading. One representative experiment of 3 is shown. Note the maximal HIF-1␣ activation with 1 mg DMOG. B, C57BL/6 mice were treated with DMOG (1 mg/mouse IP), and after 2 hours, hearts were harvested, sectioned, and stained with HIF-1␣ antibody. Cardiac tissue from a vehicle-treated mice served as control (magnification ϫ200 or ϫ600). Note that although untreated myocardium showed only weak immunoreactivity, staining for HIF-1␣ was significantly increased after DMOG treatment (arrow marks cytosolic; star shows nuclear HIF-1 staining). C, Functional consequences of DMOG treatment on myocardial infarct size. C57BL/6 mice were anesthetized and, after left ventricular catheter placement, were treated with infusion of csiR or HIF-1␣-specific siRNA/ transfection agent; they then received 1 mg DMOG or vehicle control. Two hours after DMOG treatment, mice were subjected to 60 minutes of ischemia followed by 120 minutes of reperfusion. Infarct sizes are expressed as percentage of the area at risk (meanϮSD; nϭ6). D, Representative images of infarcts from the experiment are displayed in D. E, Troponin I plasma levels were measured by ELISA (meanϮSD; nϭ6). Note the attenuated infarct size after DMOG in mice with csiR treatment and abolished cardioprotection by DMOG after HIF-1␣ siRNA. WT indicates wild type.
Figure 4.
In situ IP after in vivo siRNA repression of PHD1, PHD2, or PHD3. A-C, In vivo siRNA repression of PHD1, PHD2, or PHD3. C57BL/6 mice were treated with a left ventricular infusion of siRNA specific for PHD1, PHD2, or PHD3 or csiR. After the indicated time periods, hearts were excised; total RNA was isolated; and PHD1 (A), PHD2 (B), and PHD3 (C) transcript levels were determined by realtime reverse-transcription polymerase chain reaction. Data were calculated relative to an internal housekeeping gene (␤-actin) and are expressed as fold change vs control (0 hour of siRNA infusionϮSEM at each indicated time; nϭ6). D through F, PHD Western blot analysis of cardiac tissue after siRNA repression of individual PHDs. C57BL/6 mice were treated with control or PHD1-, PHD2-, or PHD3-specific siRNA (see above); cardiac tissues were excised at indicated time points, flash-frozen, and lysed; proteins were resolved by SDS-PAGE; and the tissues were transferred to nitrocellulose. Membranes were probed with an anti-PHD1 (D), anti-PHD2 (E), or anti-PHD3 (F) antibody. The same blots were probed for ␤-actin expression as a control for protein loading. Mice treated with csiR received 2 hours of nonspecific siRNA infusion via left ventricular catheter. One representative experiment of 3 is shown. G through I, HIF-1␣ Western blot analysis of cardiac tissue after siRNA repression of individual PHDs. C57BL/6 mice were treated with control or PHD1-, PHD2-, and PHD3-specific siRNA (see above); cardiac tissues were excised at the indicated time points, flash-frozen, and lysed; proteins were resolved by SDS-PAGE; and tissues were transferred to nitrocellulose. Membranes were probed with an anti-HIF-1␣ antibody. The blot probed for ␤-actin expression was the control for protein loading. One representative experiment of 3 is shown. J-L, Myocardial infarct size after PHD1, PHD2, or PHD3 repression. C57BL/6 mice were treated with a left ventricular infusion of siRNA specific for PHD1, PHD2, or PHD3 or csiR combined with a transfection agent (see above). After 2 hours of siRNA infusion, mice were subjected to 60 minutes of ischemia. Mice were killed after 120 minutes of reperfusion, and infarct sizes were measured. Infarct sizes are expressed as percentage of the area at risk (meanϮSD; nϭ6). Troponin I plasma levels were measured by ELISA (meanϮSD; nϭ6). Note the attenuated myocardial infarct sizes after PHD2 repression.
previous studies have shown that oxygen-dependent transcription pathways (eg, for HIF-1 or nuclear factor-B) are controlled by PHD1, PHD2, and PHD3. 5, 6, 9, 28 Thus, we hypothesized that during IP intermittent oxygen deprivation may inhibit PHD activity, resulting in cardiac HIF-1␣ stabilization. To pursue this hypothesis and to study the contribution of individual PHDs (PHD1, PHD2, and PHD3) to HIF-1 stabilization and cardioprotection by IP, we used specific siRNAs to individually target PHD1, PHD2, and PHD3. We applied siRNA for PHD1, PHD2, and PHD3 via intraventricular infusion together with a transfection agent (siPORT Amine) over 2 hours (1.5 g/g body weight). In fact, this treatment was associated with significant repression of PHD1 (0.1Ϯ0.2-fold; Figure 4A ), PHD2 (0.11Ϯ0.13-fold; Figure 4B Similarly, PHD1, PHD2, and PHD3 protein levels as assessed by Western blot analysis were repressed after specific siRNA treatment ( Figure 4D through 4F) . In contrast, treatment with a nonspecific csiR did not alter PHD1, PHD2, and PHD3 siRNA transcript or protein levels ( Figure 4A through 4F ). Studies of HIF-1␣ protein revealed that HIF-1␣ levels are elevated after PHD2 repression, whereas PHD1 or PHD3 repression was not associated with changes of HIF-1␣ protein ( Figure 4G through 4I). As a next step, we used this siRNA regimen in functional studies ( Figure 4J through 4L) . In fact, infarct sizes after 60 minutes of coronary artery ligation and 2 hours of reperfusion were not attenuated with prior siRNA repression of PHD1 ( Figure 4J ) or PHD3 ( Figure 4L ). In contrast, siRNA repression of PHD2 was associated with a degree of reduction in myocardial infarct size that was similar to IP treatment ( Figure 4K ). Infarct sizes were reduced from 43.6Ϯ3.7% of the area at risk in csiR-treated mice to 19.5Ϯ5.1% in PHD2 siRNA-treated mice (PϽ0.001; Figure 4K ). Cardioprotection after PHD2 repression also was obvious from measurements of plasma troponin I levels ( Figure 4K ), whereas plasma troponin I levels were not attenuated after siRNA repression of PHD1 or PHD3. Taken together, these data reveal a critical role of PHD2 inhibition as a mechanism of cardiac HIF-1 stabilization and attenuation of infarct sizes.
Cardiac Adenosine Levels Are Elevated With HIF Activation
On the basis of previous studies showing a critical role of extracellular adenosine generation and signaling during cardiac IP, 24,25,29 -31 we next studied the contribution of purinergic signaling pathways to HIF-dependent cardioprotection by IP. First, we measured cardiac adenosine levels with HIF activation. Consistent with previous studies, 24, 25 IP treatment was associated with elevations of cardiac adenosine levels ( Figure 5A and 5B) . However, IP-associated increases in cardiac adenosine levels were attenuated after siRNA repression of HIF-1␣, and baseline adenosine levels were elevated after HIF activation with DMOG.
HIF-1-Dependent Induction of Cardiac CD73 and the A2B Adenosine Receptor During IP
Next, we screened transcriptional responses of CD73, the key enzyme for extracellular adenosine generation, and of all 4 adenosine receptors (ARs) to cardiac IP in mice treated with specific HIF-1␣ or csiR. Consistent with previous work showing HIF-1␣ in hypoxia induction of CD73 32 or the A2B adenosine receptor (A2BAR), 33 the present studies revealed induction of CD73 and selective induction of the A2BAR in csiR-treated mice with IP. In contrast, CD73 induction and A2BAR induction with IP were abolished after siRNA repression of HIF-1␣ ( Figure 6A through 6E) . Similarly, immunohistochemical staining for the A2BAR confirmed A2BAR induction on the myocardium and on small coronary vessels after IP in csiR-treated mice, whereas HIF-1␣ siRNA treatment abolished this response ( Figure 6F ). Moreover, A2BAR transcript levels ( Figure 6G ) and protein ( Figure 6H ) were significantly elevated after treatment with the HIF activator DMOG (1 mg intraperitoneally 2 hours before cardiac biopsy). In additional studies, we measured A2BAR transcript ( Figure 6I through 6K) after in vivo siRNA repression of cardiac PHD1, PHD2, and PHD3, showing selective induction of the cardiac A2BAR after siRNA repression of PHD2. Increased A2BAR expression also was confirmed on a protein level by Western blot analysis from cardiac biopsies at the indicated time points after siRNA repression of PHD2 ( Figure 6L ). These studies reveal selective and robust induction of A2BAR during in situ IP via HIF-dependent transcriptional pathways. Figure 5 . HIF-1␣ in modulating cardiac adenosine levels during IP. A, C57BL/6 mice were treated with a left ventricular infusion of siRNA specific for HIF-1␣ (siHIF-1␣) or csiR over 4 hours and exposed to IP treatment consistent of 4 cycles of 5 minutes of myocardial ischemia followed by 5 minutes of reperfusion. Preconditioned myocardium was snap-frozen immediately after IP treatment (ϩIP); controls were sham operated (ϪIP). B, Cardiac adenosine levels 4 hours after 1 mg DMOG IP followed by IP treatment (ϩIP) or sham operation (ϪIP). Data are presented as meanϮSD (nϭ6).
HIF-1-Dependent Cardioprotection Involves CD73-Dependent Adenosine Generation and Signaling Through the A2BAR
We next pursued functional studies of in situ IP to investigate the role of the CD73-A2BAR pathway as an end point of HIFdependent cardioprotection. We performed studies of DMOGdependent cardioprotection in previously described cd73 Ϫ/Ϫ mice 32 or corresponding littermate controls matched in sex and weight. As shown in Figure 7A , DMOG-associated increases in cardiac adenosine levels were abolished in cd73 Ϫ/Ϫ mice (1 mg intraperitoneally, cardiac biopsy after 4 hours). Whereas DMOG-dependent cardioprotection (1 mg intraperitoneally) was maximal at 4 hours after DMOG treatment, baseline myocardial infarctions were increased in cd73 Ϫ/Ϫ mice, and cardioprotection by DMOG was completely abolished ( Figure 7B) . Similarly, A2BAR Ϫ/Ϫ mice showed abolished cardioprotection by DMOG ( Figure 8A and 8B) or siRNA PHD2 treatment ( Figure 8C and 8D), whereas cardioprotection in matched littermate controls was maximal 4 hours after DMOG or after 4 hours of PHD2-siRNA treatment.
Discussion
In the present study, we pursued the contribution of HIF-1 to cardiac IP using loss-and gain-of-function studies of HIF-1␣. For this purpose, we used a technique of cardiac in vivo siRNA repression of selective genes via intraventricular infusion of specific siRNA followed by studies of murine in situ preconditioning and myocardial infarction. We first gained insight from Western blot analysis for HIF-1␣ from preconditioned myocardium showing activation of HIF-1␣ after IP treatment. Whereas Figure 6 . HIF-1 in CD73 and AR expression during IP. A through E, CD73 and AR transcript levels after IP with siRNA repression of HIF-1␣. C57BL/6 mice were treated with a left ventricular infusion of siRNA specific for HIF-1␣ or csiR. After 2 hours, in situ preconditioning consisting of 4 cycles of ischemia/ reperfusion (5 minutes each) followed by indicated times of reperfusion (0 to 90 minutes) was performed. Hearts were excised; total RNA was isolated; and transcript levels of CD73 (A), A1AR (B), A2AAR (C), A2BAR (D), or A3AR (E) were determined by real-time reversetranscription polymerase chain reaction. Data were calculated relative to an internal housekeeping gene (␤-actin) and are expressed as fold change vs control (0 hour of siRNA infusionϮSEM at each indicated time; nϭ6). F, Preconditioned myocardial tissues from hearts treated with siRNA specific for HIF-1␣ or csiR were harvested, sectioned, and stained with A2BAR antibody (magnification ϫ600). G, DMOG treatment. To study the effects of DMOG on cardiac A2BAR expression, C57BL/6 mice were treated intraperitoneally with 1 mg. Hearts were excised after the indicated time periods (0 to 2 hours) and flash-frozen; total RNA was isolated; and transcript levels of A2BAR were determined by real-time reverse-transcription polymerase chain reaction. Data were calculated relative to an internal housekeeping gene (␤-actin) and are expressed as fold change vs control (nϭ6). H, C57BL/6 mice were treated intraperitoneally with DMOG (1 mg). After 2 hours, hearts were harvested, flash-frozen, and lysed; proteins were resolved by SDS-PAGE; and tissues were transferred to nitrocellulose. Membranes were probed with an anti-A2BAR antibody. The same blot was probed for ␤-actin expression as a control for protein loading. One representative experiment of 3 is shown. I-K, A2BAR induction after PHD repression. C57BL/6 mice were treated with a left ventricular infusion of siRNA specific for PHD1-3 or csiR. After the indicated time periods (0 to 2 hours), hearts were excised; total RNA was isolated; and transcript levels of A2BAR after PHD1 (I), PHD2 (J), or PHD3 (K) repression were determined by real-time reverse-transcription polymerase chain reaction. Data were calculated relative to an internal housekeeping gene (␤-actin) and are expressed as fold change vs control (0 hour of siRNA infusionϮSEM at each indicated time; nϭ6). L, A2BAR Western blot analysis of cardiac tissue after siRNA repression of PHD2. C57BL/6 mice were treated with control or PHD2-specific siRNA. Cardiac tissues were excised at indicated time points, flash-frozen, and lysed; proteins were resolved by SDS-PAGE; and tissues were transferred to nitrocellulose. Membranes were probed with an anti-PHD2 antibody. The same blots probed for ␤-actin expression were used as a control for protein loading. Control mice were treated with csiR for 2 hours. One representative experiment of 3 is shown.
the cardioprotective effects of IP were abolished with siRNA repression of HIF-1␣, pharmacological or genetic activation of HIF-1␣ was associated with a degree of cardioprotection similar to IP treatment itself. Additional studies of end-point signaling after HIF activation suggested a critical role of HIF-dependent activation of purinergic signaling pathways involving CD73 and A2BAR. Taken together, these studies reveal a central role of HIF-1 in myocardial IP via transcriptional activation of purinergic signaling pathways to increase myocardial resistance to subsequent ischemic tissue injury and suggest pharmacological strategies of HIF-1 activation in the treatment of acute myocardial ischemia.
Previous studies have shown that the human A2BAR promoter has a functional HIF-1 binding site. 33 In fact, studies using constructs of the human A2BAR promoter, site-directed mutagenesis of the HIF binding site, and HIF loss and gain of function strongly suggest HIF-1 in hypoxia inducibility of the human A2BAR. 33 Moreover, transcription factor binding studies revealed direct binding of HIF-1 to the putative promoter region. Similar to the human A2BAR promoter, the murine A2BAR promoter has 2 putative HIF binding sites. Previous studies have not directly addressed HIF binding to the murine A2BAR promoter. However, other studies showed a robust induction of the murine A2BAR with ambient hypoxia in vivo 34 or during IP treatment. 24 In addition, the present studies show loss of A2BAR inducibility after HIF-1 repression during IP ( Figure 6 ) and suggest a central role of HIF-1 in A2BAR induction during murine in situ IP. Moreover, and consistent with the present studies, previous work has suggested a critical role of HIF-1 in cardioprotection. As such, a study of cardiac ischemia/reperfusion injury found cardioprotective effects with siRNA-mediated repression of PHD2 and activation of HIF-1␣. 35 Similarly, a very elegant study of gene-targeted mice for HIF-1␣ found complete loss of cardioprotection by IP in heterozygote mice (HIF-1␣ ϩ/Ϫ mice). 36 Other excellent studies have examined preconditioning phenomena by hypoxic preexposure in association with HIF-1. Exposure of wild-type mice to intermittent hypoxia resulted in protection of isolated hearts against ischemia/ reperfusion injury 24 hours later. However, cardiac protection induced by intermittent hypoxia was lost in HIF-1␣ ϩ/Ϫ mice. 37 It is important to point out that the use of DMOG as an HIF-1 inducer serves mainly as a positive control in the present study, although this reagent obviously is not specific for HIF-1␣ activation. For example, a recent study revealed that the stability of the transcription factor nuclear factor-B is regulated during hypoxia by PHDs in a manner somewhat similar to HIF-1␣. 28 Thus, it is conceivable that PHD inhibition with DMOG also could lead to changes in nuclear factor-B activity. Moreover, noncardiospecific effects of DMOG (eg, increases in hematocrit or red cell volume, direct effects of erythropoietin) 37-39 may have contributed to the observed cardioprotective effects. It is also important to note that intermittent ischemia/reperfusion appears to be a very robust inducer of HIF-1␣ expression and activity (possibly even more than hypoxia alone), as well as the expression of other HIF isoforms, which is consistent with results over the past several years from a number laboratories. 40, 41 Functional studies using a tissue-specific approach for selectively targeting different HIF isoforms will elucidate their individual contributions to cardioprotection in the near future.
Taken together, the present studies reveal a critical role of HIF-1 in the transcriptional coordination of adaptive responses elicited by IP of the murine heart. In fact, stabilization of HIF-1 is an essential component of myocardial Figure 7 . Contribution of the CD73 to HIF-dependent cardioprotection. A, Cardiac adenosine levels. Cd73 Ϫ/Ϫ mice or matched littermate controls (cd73 ϩ/ϩ ) were treated with DMOG (1 mg intraperitoneally 4 hours before cardiac biopsy) or vehicle control. Hearts were snapfrozen, and cardiac adenosine levels were determined by high-performance liquid chromatography. Data are presented as meanϮSD (nϭ6). B, DMOG cardioprotection in cd73 Ϫ/Ϫ mice. Cd73 Ϫ/Ϫ mice or age-and sex-matched littermate control mice (cd73 ϩ/ϩ ) received 1 mg of the HIF-1 activator DMOG intraperitoneally. At the indicated time periods after DMOG treatment (60 to 240 minutes; C indicates control [vehicle only]), mice were subjected to 60 minutes of coronary occlusion followed by 2 hours of reperfusion, and infarct sizes were determined. Infarct sizes are expressed as percentage of the area at risk (C indicates control [no DMOG]; meanϮSD; nϭ6). protection conferred by IP. HIF-1 end-point signaling involves enhancement of purinergic signaling pathways through the A2BAR. Extension of these findings will reveal whether activation of HIF-1 signaling pathways will serve as an approach to acute myocardial ischemia. Figure 8 . HIF-1-dependent cardioprotection and A2BAR signaling. A, DMOG cardioprotection in A2BAR Ϫ/Ϫ mice. A2BAR Ϫ/Ϫ mice or age-, gender-, and sex-matched littermate control mice (A2BAR ϩ/ϩ ) received 1 mg of the HIF-1 activator DMOG intraperitoneally. At the indicated time periods after DMOG treatment (60 to 240 minutes; C indicates control [vehicle only]), mice were subjected to 60 minutes of coronary occlusion followed by 2 hours of reperfusion, and infarct sizes were determined. Infarct sizes are expressed as percentage of the area at risk (C indicates control [no DMOG]; meanϮSD; nϭ6). B, Troponin I plasma levels were measured by ELISA (meanϮ SD; nϭ6). C, PHD2 repression in A2BAR Ϫ/Ϫ mice. A2BAR Ϫ/Ϫ mice or age-and sex-matched littermate controls (A2BAR ϩ/ϩ mice) were treated with a left ventricular infusion of siRNA specific for PHD2 or csiR combined with a transfection agent. After the indicated time periods of siRNA infusion (60 to 240 minutes; C indicates control [vehicle only]), mice were subjected to 60 minutes of coronary ischemia followed by 2 hours of reperfusion, and infarct sizes were determined as above (meanϮSD; nϭ6). D, Troponin I plasma levels (meanϮSD; nϭ6).
